Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: June 6th 2024 | Updated: March 8th 2025
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
Published: January 6th 2023 | Updated: March 8th 2025
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: January 12th 2022 | Updated: March 8th 2025
Part 1: PARP Inhibition Recommendations in Advanced Ovarian Cancer
Published: March 4th 2025 | Updated: March 8th 2025
Two Denosumab Biosimilars Pocket FDA Approval in Multiple Indications